Immune Synapse Engagement as a Novel Approach for Cancer Immunotherapy
Monoclonal antibodies (mAbs) targeting immune checkpoints have revolutionized cancer treatment but exhibit several challenges, most notably, limited intratumor efficacy and relatively low patient response rates. Endowing these mAb...
Monoclonal antibodies (mAbs) targeting immune checkpoints have revolutionized cancer treatment but exhibit several challenges, most notably, limited intratumor efficacy and relatively low patient response rates. Endowing these mAbs with immune-cell-recruitment capabilities may offer the solution to these drawbacks. This assumption is based on our recent findings that the effectivity of a given checkpoint mAb relies not only on its binding to its target T-cell’s receptor but also on the direct interaction of the targeted T-cell with dendritic cells (DCs). Our results suggest that the low-frequency or dysfunctionality of such stimulating immune synapses following checkpoint mAb treatments hinder their anti-tumor efficacy. Therefore, the outcome of not taking this T-cell-DC licensing loop mechanism into account in mAb design is suboptimal checkpoint mAbs.
To overcome these limitations, we propose here to develop a series of bi- and muti-specific immune synapse engager antibodies as a new approach to enforce immune interactions for cancer immunotherapy. We will apply in-vivo genetic tools and high-dimensional analysis of the immune response on the spatial, cellular, proteomic and transcriptomic levels to provide critical insights into immune synapses that mediate effective T-cell anti-tumor activity. We will then harness this knowledge to apply antibody-engineering approaches and treatment regimens to maximize anti-tumor activity. We will explore and target T-cell-DC synapses that enable antagonistic (Aim 1) and agonistic (Aim 2) checkpoint mAbs and additional types of immune cell interactions underlying favourable immune surveillance of tumors (Aim 3). This study will introduce a novel approach for cancer immunotherapy using drugs that engage physical crosstalk between key immune cells. Ideally, this study will yield reagents with potent anti-tumor efficacy and well-characterized in-vivo activities that can be readily translated for evaluation in human patients.ver más
02-11-2024:
Generación Fotovolt...
Se ha cerrado la línea de ayuda pública: Subvenciones destinadas al fomento de la generación fotovoltaica en espacios antropizados en Canarias, 2024
01-11-2024:
ENESA
En las últimas 48 horas el Organismo ENESA ha otorgado 6 concesiones
01-11-2024:
FEGA
En las últimas 48 horas el Organismo FEGA ha otorgado 1667 concesiones
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.